Charles River Laboratories International Inc (NYSE: CRL) has a price-to-earnings ratio of 650.80x that is above its average ratio. Additionally, the 36-month beta value for CRL is 1.38. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 15 rating it as “hold,” and 2 rating it as “sell.”
The public float for CRL is 50.57M and currently, short sellers hold a 5.80% ratio of that float. The average trading volume of CRL on March 14, 2025 was 1.07M shares.
CRL) stock’s latest price update
Charles River Laboratories International Inc (NYSE: CRL)’s stock price has plunge by -2.15relation to previous closing price of 170.59. Nevertheless, the company has seen a -1.38% plunge in its stock price over the last five trading sessions. businesswire.com reported 2025-03-04 that PORTO, Portugal & SAN FRANCISCO–(BUSINESS WIRE)–FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney’s ongoing strategic growth plan, and will significantly bolster the Company’s antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its gl.
CRL’s Market Performance
Charles River Laboratories International Inc (CRL) has seen a -1.38% fall in stock performance for the week, with a 7.77% gain in the past month and a -17.26% plunge in the past quarter. The volatility ratio for the week is 4.46%, and the volatility levels for the past 30 days are at 3.44% for CRL. The simple moving average for the past 20 days is 1.00% for CRL’s stock, with a -13.90% simple moving average for the past 200 days.
Analysts’ Opinion of CRL
Many brokerage firms have already submitted their reports for CRL stocks, with Citigroup repeating the rating for CRL by listing it as a “Neutral.” The predicted price for CRL in the upcoming period, according to Citigroup is $175 based on the research report published on March 04, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see CRL reach a price target of $188. The rating they have provided for CRL stocks is “Neutral” according to the report published on March 03rd, 2025.
CRL Trading at -1.19% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.25% of loss for the given period.
Volatility was left at 3.44%, however, over the last 30 days, the volatility rate increased by 4.46%, as shares surge +8.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.33% lower at present.
During the last 5 trading sessions, CRL fell by -1.38%, which changed the moving average for the period of 200-days by -23.27% in comparison to the 20-day moving average, which settled at $165.27. In addition, Charles River Laboratories International Inc saw -9.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from FOSTER JAMES C, who purchase 6,075 shares at the price of $165.01 back on Feb 20 ’25. After this action, FOSTER JAMES C now owns 183,639 shares of Charles River Laboratories International Inc, valued at $1,002,436 using the latest closing price.
Girshick Birgit, the Corporate Executive VP & COO of Charles River Laboratories International Inc, purchase 1,514 shares at $164.63 during a trade that took place back on Feb 20 ’25, which means that Girshick Birgit is holding 55,058 shares at $249,250 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.32 for the gross margin
The net margin for Charles River Laboratories International Inc stands at 0.0. The total capital return value is set at 0.04. Equity return is now at value 0.45, with 0.20 for asset returns.
Based on Charles River Laboratories International Inc (CRL), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.79. The interest coverage ratio of the stock is 2.08.
Currently, EBITDA for the company is 581.14 million with net debt to EBITDA at 4.35. When we switch over and look at the enterprise to sales, we see a ratio of 2.73. The receivables turnover for the company is 5.62for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
In conclusion, Charles River Laboratories International Inc (CRL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
